# EDGAR Filing Document

**Accession Number:** 0001796129
**File Stem:** 0001193125-23-000177
**Filing Date:** 2023-1
**Character Count:** 6620
**Document Hash:** 9eb5422aeefea1fbb5332a27becdc258
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-000177.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001193125-23-000177

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20221230

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vincerx Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001796129
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 833197402
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39244
- **FILM NUMBER:** 23500065

**BUSINESS ADDRESS:**
- **STREET 1:** 260 SHERIDAN AVENUE
- **STREET 2:** SUITE 400
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94306
- **BUSINESS PHONE:** 650-800-6676

**MAIL ADDRESS:**
- **STREET 1:** 260 SHERIDAN AVENUE
- **STREET 2:** SUITE 400
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94306

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vincera Pharma, Inc.
- **DATE OF NAME CHANGE:** 20201223

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LifeSci Acquisition Corp.
- **DATE OF NAME CHANGE:** 20191206

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): December 30, 2022

------

## Vincerx Pharma, Inc.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39244** | **83-3197402** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **260 Sheridan Avenue, Suite 400**<br> **Palo Alto, California** | **94306** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

(650) 800-6676

#### (Registrant's telephone number, including area code)

#### N/A

#### (Former name or former address, if changed since last report.)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.0001 par value per share | VINC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

Effective December 31, 2022, Dr. Andrew I. McDonald and Christopher P. Lowe resigned as members of the board of directors (the "Board") of Vincerx Pharma, Inc. (the "Company"). Dr. McDonald had served as a member of the Board since the initial public offering of LifeSci Acquisition Corp. in March 2020, and Mr. Lowe had served as a member of the Board and as chair of the Audit Committee of the Board since the Business Combination. As stated in their resignation letters received on December 30, 2022, copies of which are attached as Exhibits 17.1 and 17.2, Dr. McDonald and Mr. Lowe resigned as a result of different views regarding Company strategy. There was no disagreement with the Company's auditors or financial statements.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

---

| | |
|:---|:---|
| (d) | Exhibits. |
| 17.1 | [Letter from Dr. McDonald.](d637069dex171.htm) |
| 17.2 | [Letter from Mr. Lowe.](d637069dex172.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 2, 2023

---

| | |
|:---|:---|
| VINCERX PHARMA, INC. | VINCERX PHARMA, INC. |
| By: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ Raquel E. Izumi |
|  | Raquel E. Izumi |
|  | President and Chief Operations Officer |

---

## Exhibit 17.1

**Exhibit 17.1** 

Ahmed Handy MD

Chairman of the Board of Directors and CEO

Vincerx Corporation

Dear Vincerx team

I am writing to tender my resignation from the Board of Directors of Vincerx Corporation (the "Company"), effective December 31, 2022.

My decision to resign from the Company's board of directors is the result of assessing the company strategy, upon which our views differ. I do not have any disagreement with the Company's auditors or financials.

Best regards,

Andrew McDonald

## Exhibit 17.2

**Exhibit 17.2** 

Ahmed Handy MD

Chairman of the Board of Directors and CEO

Vincerx Corporation

Dear Vincerx team

I am writing to tender my resignation from the Board of Directors of Vincerx Corporation (the "Company"), effective December 31, 2022.

My decision to resign from the Company's board of directors is the result of assessing the company strategy, upon which our views differ. I do not have any disagreement with the Company's auditors or financials.

Best regards,

Chris Lowe